36 Appointments

Chiesi Group has appointed David Khougazian as Group Chief Executive Officer (CEO). Khougazian joins Chiesi following an international career spanning more than 25 years across the global healthcare and life sciences sectors.
Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organisational development.

Following a thorough selection process led by the Board of Directors, Khougazian will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group Chief Financial Officer.

The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) has appointed Brad Schneider as Chief Operating Officer (COO). Schneider brings more than two decades of experience in infectious disease research, global health operations and AI biosecurity to his new role.

Schneider joins QBI from Vaccines for Communities (V4C), where he served as CEO. Prior to that, he served in multiple senior leadership roles at San Francisco-based Pinpoint Science including CEO, Chief Research Officer and Head of Infectious Disease, and currently serves as Chairman of the Board.

As CEO, he directed all scientific, operational and regulatory activities and spearheaded the development and validation of a novel bioelectronic diagnostic device. Schneider began his scientific career at the CDC’s Division of Vector-Borne Infectious Disease.

Nuclera has appoint Carl Raimond as Chief Executive Officer (CEO). Michael Chen, Nuclera’s co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships.

Raimond joins from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1bn acquisition by Thermo Fisher Scientific in 2023.

An experienced life sciences executive, Raimond has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. As Chief Scientific and Business Officer, Chen will focus on scientific strategy, market development and strategic partnerships.